The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

LigaChem HER2 drug shrank tumors in 5 of 10 patients after Enhertu

Nov 2, 2026 03:55 (2h ago)

Verifying

LigaChem Biosciences’ investigational HER2 drug shrank tumors in breast cancer patients.
The drug reduced tumors in 5 of 10 patients previously treated with Enhertu.
The treatment is built on LigaChem Biosciences’ antibody-drug conjugate platform.